Eagle swoops for rights to pneumonia candidate
US drugmaker Eagle Pharmaceuticals (Nasdaq: EGRX) has entered into a worldwide licensing agreement with Swiss biotech Combioxin for the commercial rights to CAL02, an antitoxin agent ready for Phase IIb/III development for the treatment of severe pneumonia in combination with traditional antibacterial drugs.
The deal will make Eagle solely responsible for further clinical development of CAL02 and the company will make an undisclosed upfront payment, followed by additional payments upon achievement of development milestones, regulatory approval and based upon commercial sales.
"This deal, along with the recent landiolol transaction, broadens our pipeline and provides opportunities for continued leadership in the hospital acute care space"Eagle expects to invest $35 million to achieve interim results, which are expected during the first half of 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze